EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Identifying Hemophagocytic Lymphohistiocytosis and Describing Outcomes Using Computable Phenotypes: Retrospective Cohort Study

Suheyla Ocak iD, Martin Yi iD, Agata Wolochacz iD, Ida Mehrdadi iD, Ahmed Naqvi iD, Sumit Gupta iD, Lillian Sung iD, Adam P Yan iD

JMIR Cancer · 26.03.2026 · 12 · e87347-e87347

DOI: 10.2196/87347 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift JMIR Cancer, online erschienen am 26.03.2026. Verfasst von Suheyla Ocak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada, 1 4168131500. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Electronic Health Records. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that requires rapid diagnosis and intervention. However, identifying these patients is difficult because the HLH-2004 diagnostic criteria are complex and not always captured systematically in electronic health records (EHRs). Furthermore, it is unclear how clinicians use these criteria to diagnose HLH and make treatment decisions. There is a critical need for validated computable phenotypes to accurately identify patients and study treatment-related outcomes in HLH.

Objective

The aim of this study is to compare different approaches to using the EHR to build computable phenotypes of patients with HLH and to evaluate characteristics and outcomes of patients meeting the HLH-2004 diagnostic criteria who received HLH-directed therapies compared to those who did not.

Methods

Three approaches to computable phenotype development in the EHR were taken by identifying patients (1) with an HLH-specific International Statistical Classification of Diseases, Tenth Revision ( ICD-10 ) code, (2) with an HLH-specific treatment plan, and (3) meeting the HLH-2004 clinical criteria for diagnosis of HLH. Among patients who met the HLH-2004 criteria, we evaluated the characteristics and outcomes of patients who received HLH-directed therapies compared to those who did not. HLH treatment was defined as either any chemotherapy or HLH-specific therapy (dexamethasone, methylprednisolone, anakinra, ruxolitinib, cyclosporine, etoposide, or emapalumab).

Results

We identified 388 patients with possible HLH across the three cohorts. An HLH ICD-10 diagnosis (n=220) and meeting 5 or more clinical criteria (n=245) were much more common than a HLH treatment plan (n=42). Among the patients meeting HLH-2004 clinical criteria, 193 (79%) received HLH-directed therapy. There was no difference in any specific HLH criteria between those who did and did not receive HLH-directed therapy. In-hospital mortality was very high among both groups and was 15% among those who received HLH-directed therapy and 13.5% among those who did not receive HLH-directed therapy. Among 1325 patients with an elevated ferritin and fever, only 252 (19%) met >5 clinical criteria.

Conclusions

Constructing HLH cohorts from EHR data is challenging, with diagnosis codes, treatment plans, and clinical criteria each capturing distinct but overlapping populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticElectronic Health RecordsHumansRetrospective StudiesFemalePhenotypeMaleChild, PreschoolChildInfantAdolescent

Stichwörter der Autor:innen

HLHcomputable phenotypeelectronic health recordhemophagocytic lymphohistiocytosisoncologypediatrics

Autor:innen und Institutionen

  • Division of Haematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada, 1 4168131500.
  • Department of Pediatric Hematology and Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.

ORCID-Profile: Suheyla Ocak, Martin Yi, Agata Wolochacz, Ida Mehrdadi, Ahmed Naqvi, Sumit Gupta, Lillian Sung, Adam P Yan

Zitieren

APA

Ocak, S., Yi, M., Wolochacz, A., Mehrdadi, I., Naqvi, A., Gupta, S., Sung, L., & Yan, A. P. (2026). Identifying Hemophagocytic Lymphohistiocytosis and Describing Outcomes Using Computable Phenotypes: Retrospective Cohort Study. JMIR Cancer, 12, e87347-e87347. https://doi.org/10.2196/87347

Vancouver

Ocak S, Yi M, Wolochacz A, Mehrdadi I, Naqvi A, Gupta S, et al. Identifying Hemophagocytic Lymphohistiocytosis and Describing Outcomes Using Computable Phenotypes: Retrospective Cohort Study. JMIR Cancer. 2026;12:e87347-e87347. doi:10.2196/87347

BibTeX
@article{Ocak2026,
  author = {Ocak, Suheyla and Yi, Martin and Wolochacz, Agata and Mehrdadi, Ida and Naqvi, Ahmed and Gupta, Sumit and Sung, Lillian and Yan, Adam P},
  title = {Identifying Hemophagocytic Lymphohistiocytosis and Describing Outcomes Using Computable Phenotypes: Retrospective Cohort Study},
  journal = {JMIR Cancer},
  year = {2026},
  volume = {12},
  pages = {e87347--e87347},
  doi = {10.2196/87347}
}
Kostenlos starten →